Evidence map›Paper›PMID 33424228›Full record

ReviewBreast cancer : basic and clinical research2020

A Brief Overview of the Paradoxical Role of Glucocorticoids in Breast Cancer.

Ekaterina M Zhidkova, Evgeniya S Lylova, Alena V Savinkova, Sergey A Mertsalov, Kirill I Kirsanov, Gennady A Belitsky, Marianna G Yakubovskaya, Ekaterina A Lesovaya

Open access · goldAbstract readReview
In one paragraph

Review in Breast cancer : basic and clinical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Revisiting the use of steroids in oncology.Medical oncology (Northwood, London, England) · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Nutritional Sensor REDD1 in Cancer and Inflammation: Friend or Foe?International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ekaterina M ZhidkovaDepartment of Oncology, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.ORCID https://orcid.org/0000-0003-3318-9391
Evgeniya S LylovaDepartment of Oncology, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.ORCID https://orcid.org/0000-0001-6388-1624
Alena V SavinkovaDepartment of Oncology, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.
Sergey A MertsalovI.P. Pavlov Ryazan State Medical University, Ryazan, Russia.
Kirill I KirsanovDepartment of Oncology, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.ORCID https://orcid.org/0000-0002-8599-6833
Gennady A BelitskyDepartment of Oncology, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.
Marianna G YakubovskayaDepartment of Oncology, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.
Ekaterina A LesovayaDepartment of Oncology, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.ORCID https://orcid.org/0000-0002-1967-9637
Ryazan State Medical University named after Academician I.P. Pavlov · RUPeoples' Friendship University of Russia · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucocorticoids (GCs) are stress hormones that play multiple roles in the regulation of cancer cell differentiation, apoptosis, and proliferation. Some types of cancers, such as hematological malignancies, can be effectively treated by GCs, whereas the responses of epithelial cancers to GC treatment vary, even within cancer subtypes. In particular, GCs are frequently used as supporting treatment of breast cancer (BC) to protect against chemotherapy side effects. In the therapy of nonaggressive luminal subtypes of BC, GCs can have auxiliary antitumor effects due to their cytotoxic actions on cancer cells. However, GCs can promote BC progression, colonization of distant metastatic sites, and metastasis. The effects of GCs on cell proliferation vary with BC subtype and its molecular profile and are realized via the activation of glucocorticoid receptor (GR), a well-known transcriptional factor involved in the regulation of the expression of multiple genes, cell-cell adhesion, and cell migration and polarity. This review focuses on the roles of GC signaling in the adhesion, migration, and metastasis of BC cells. We discuss the molecular mechanisms of GC actions that lead to BC metastasis and propose alternative pharmacological uses of GCs for BC treatment.

Indexed as

Breast cancerbreast cancer metastasisglucocorticoidglucocorticoid receptorREDD1selective glucocorticoid receptor agonists (SEGRA)

Identifiers

PMID33424228
PMCPMC7755940
OpenAlexW3116151248

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.